NAD+ therapy can supposedly increase your energy, focus, and metabolism, improve your cardiovascular health, and help you detox from alcohol and drugs. All this, of course, sounds incredibly unlikely—so I thought I’d see for myself.
In the meantime, practitioners of this new kind of mental healthcare can use ketamine as their psychedelic agent; and some studies, such as the one Grant participated in, are even government funded. The Ketamine for Reduction of Alcoholic Relapse (Kare) study is a novel attempt to ease the huge burden on the NHS caused by alcohol-related illnesses.
Depression afflicts 16 million Americans. One third don’t get better with treatment. A surprising new drug may change that
Sean Spencer is a pretty successful entrepreneur in LA’s startup community but he also struggles with depression, so he uses ketamine to help with his lows.
Could the club drug, ketamine, be the best hope for curing chronic depression? Every year millions of Americans struggle with major depression, but 30% of these people don’t get any better on anti-depressants. However, low dose ketamine infusions can offer complete relief from depressive thoughts and feelings in as little as 1-2 hours.
NAD+ is popular among the “anti-aging community,” thanks to a Harvard Medical School study that found it rewound “aspects of age-related demise in mice.” It’s also supposedly good for: detoxing from alcohol and drugs, increasing energy and focus, reducing chronic fatigue, increasing your metabolism, and improving your cardiovascular health.
A mind-altering drug called ketamine is changing the way some doctors treat depression.
Recent research suggests it may be possible to reverse mitochondrial decay with dietary supplements that increase cellular levels of a molecule called NAD (nicotinamide adenine dinucleotide). But caution is due…
It is either the most exciting new treatment for depression in years or it is a hallucinogenic club drug that is wrongly being dispensed to desperate patients in a growing number of clinics around the country.
Carlos Zarate, M.D., speeds up treatment for major depression at the National Institutes of Health (NIH) Intramural Research Program (IRP). Dr. Zarate is Chief of the Experimental Therapeutics & Pathophysiology Branch and the Section on the Neurobiology and Treatment of Mood Disorders at the National Institute of Mental Health (NIMH).